Evaluation of an Anti-Shivering Protocol Cardiac Arrest
Evaluation of an Anti-Shivering Protocol for Targeted Temperature Management Following Cardiac Arrest
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Methodist Dallas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years
- Diagnosis of cardiac arrest
- Initiation of TTM via Arctic Sun® device
Exclusion Criteria:
- Initiation of TTM > 12 hours after cardiac arrest
- Receiving NMBs for an indication other than TTM
- Early termination of TTM (less than 24 hours)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NMB usage
Time Frame: June 1, 2017 - May 31, 2021
|
vecuronium or cisatracurium
|
June 1, 2017 - May 31, 2021
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NMB usage
Time Frame: June 1, 2017 - May 31, 2021
|
Proportion of patients that required any vecuronium boluses Number of vecuronium boluses administered Proportion of patients that required initiation of cisatracurium infusion |
June 1, 2017 - May 31, 2021
|
|
Patients discharged home
Time Frame: June 1, 2017 - May 31, 2021
|
Proportion of patients discharged home
|
June 1, 2017 - May 31, 2021
|
|
Patients with a breakthrough fever (temperature > 38°C) in the first 72 hours of TTM initiation
Time Frame: First 72 hours of TTM initiation
|
Proportion of patients with a breakthrough fever (temperature > 38°C) in the first 72 hours of TTM initiation
|
First 72 hours of TTM initiation
|
|
Proportion of patients cooled to 33°C versus 36°C
Time Frame: June 1, 2017 - May 31, 2021
|
number of patients at desired temperature range
|
June 1, 2017 - May 31, 2021
|
|
Time to target temperature from initiation of TTM
Time Frame: June 1, 2017 - May 31, 2021
|
time in minutes
|
June 1, 2017 - May 31, 2021
|
|
ICU length of stay
Time Frame: June 1, 2017 - May 31, 2021
|
number of days
|
June 1, 2017 - May 31, 2021
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tamara Reiter, PharmD, Methodist
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 042.PHA.2021.D
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.